Claims
- 1. A method of inhibiting bronchoconstriction, which comprises administering to the circulatory system of a mammalian host an effective amount of a compound having the structural formula ##STR53## and including all stereoisomers thereof; wherein A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2, B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR54## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR55## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR56## or OR.sup.2 wherein R.sup.2 is H; Y is substituted alkyl (wherein the substituent is halo, lower alkoxy, alkyl-aryl, haloalkyl, cycloalkyl or alkylcycloalkyl); aryl-lower alkyl; alkenyl containing 3 to 6 carbons; alkynyl containing 3 to 6 carbons; aryl (which may be unsubstituted or substituted with lower alkyl, halogen or lower alkoxy); cycloalkyl; substituted cycloalkyl; cycloalkylalkyl; substituted cycloalkylalkyl; or phenoxymethyl;
- wherein alkyl or lower alkyl by itself or as part of another group contains 1 to 12 carbons, cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion, aryl by itself or as part of another group refers to a monocyclic or bicyclic armomatic ring which contains 6 to 10 carbons in the ring portion, and the cycloalkyl group by itself or as part of another group may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups or lower alkoxy groups (the above substituents not being adjacent to sterically hindered groups);
- and represents a single bond or double bond, with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl, or a pharmaceutically acceptable salt thereof.
- 2. The method as defined in claim 1 wherein X in said compound is ##STR57## and wherein Q is phenyl or lower alkyl.
- 3. The method as defined in claim 1 wherein Y in said compound is phenyl, phenyl-alkyl, cycloalkyl or cycloalkyl-alkyl.
- 4. The method as defined in claim 1 wherein Y is ##STR58##
- 5. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.beta.(5Z),3.alpha.(1E,3S*),4.beta.[-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z),3.alpha.(1E,3R*),4.beta.]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 6. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.beta.(5Z),3.alpha.(1E,3S*),4.beta.]-7-[3-(3-hydroxy-4,4-dimethyl-1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z),3.alpha.(1E,3R*),4.beta.]- 7-[3-(3-hydroxy-4,4-dimethyl-1-octenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 7. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.beta.(5Z),3.alpha.(1E,3S*),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.beta.(5Z),3.alpha.(1E,3R*),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 8. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3S*),4.beta.]-7-[3-(3-cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid.
- 9. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.beta.(5Z),3.alpha.(1E,3S*),4.beta.]-7-[3-(4-cyclohexyl-3-hydroxy-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoic acid or [1.beta.,2.beta.(5Z),3.alpha.(1E,3R*),4.beta.]-7-[3-(4-cyclohexyl-3-hydroxy-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 10. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z,3.alpha.(1E,3S*),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-butenyl)-7-oxabicyclo[2.2.1]hept-2-yll-5-heptenoic acid or its methyl ester.
- 11. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.alpha.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.beta.), 4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-(3-hydroxy-4-phenyl-1-pentenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 12. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.), 4.beta.]-7-[3-[3-hydroxy-4-(2-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-4-(2-methylphenyl)-1-butenyl]-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 13. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-[3-hydroxy-4-(3-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-4-(3-methylphenyl)-1-butenyl]-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 14. The method as defined in claim 1 wherein said compound has the name 1.beta.,2.alpha.(5Z), 3.alpha.(1E, 3.alpha.),4.beta.]-7-[3-3-hydroxy-4-methyl-4-phenyl-1-pentenyl)-7-oxabicyclo 2.2.1 ]hept-2-yl]-5-heptenoic acid or 1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-3-hydroxy-4-methyl-4-phenyl-1-pentenyl)-7-oxabicyclo [2.2.1]hept-2-yl-5-heptenoic acid esters of each.
- 15. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E, 3.alpha.),4.beta.-7-[3-[3-hydroxy-3-(1-methylcyclohexyl)-1-propenyl-7-oxabicyclo [2.2.1 ]hept-2 -yl-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-3-(1-methyl-cyclohexyl)-1-propenyl-]7-oxabicyclo[2.2.1 ]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 16. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.),4.beta.]-7-[3-[3-hydroxy-4-(4-methylphenyl)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-[3-hydroxy-4-methyl-phenyl)-1-butenyl]-7-oxabicyclo [2.2.1]hept-2-yl-5-heptenoic acid or methyl esters of each.
- 17. The method as defined in claim 1 wherein said compound has the name [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.alpha.),4.beta.]-7-[3-3-hydroxy-4-phenyl-1-hexenyl-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid; or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.alpha.,4.beta.),4.beta.]-7-[3-3-hydroxy-4-phenyl-1-hexenyl)-7-oxabicyclo [2.2.1]hept-2-yl]-5-heptenoic acid or [1.beta.,2.alpha.(5Z),3.alpha.(1E,3.beta.),4.beta.]-7-[3-3-hydroxy-4-phenyl-1-heptenyl)-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid or methyl esters of each.
- 18. The method as defined in claim 1 wherein said compound is administered in an amount within the range of from about 1 to about 100 mg/kg.
- 19. A composition for inhibiting bronchoconstriction comprising an effective amount of a compound having the structural formula ##STR59## and including all stereoisomers thereof; wherein A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2, B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR60## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR61## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR62## or OR.sup.2 wherein R.sup.2 is H; Y is aryl-lower alkyl; alkenyl, alkynyl cycloalkyl; substituted cycloalkyl; cycloalkylalkyl, substituted cycloalkylalkyl, or phenoxymethyl;
- wherein alkyl or lower alkyl by itself or as part of another group contains 1 to 12 carbons, cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion, aryl by itself or as part of another group refers to a monocyclic or bicyclic armomatic ring which contains 6 to 10 carbons in the ring potion, and the cycloalkyl group by itself or as part of another group may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups or lower alkoxy groups (the above substituents not being adjacent to sterically hindered groups);
- and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl, or a pharmaceutically acceptable salt thereof, and a pharmaceutically accpetable carrier therefor.
- 20. A method of inhibiting bronchoconstriction associated with asthma, which comprises administering to a mammalian host an effective amount of a compound having the structural formula ##STR63## and including all stereoisomers thereof; wherein A and B may be the same or different and A is CH.dbd.CH or (CH.sub.2).sub.2, B is CH.dbd.CH, C.tbd.C, or (CH.sub.2).sub.2 ; m is 1 to 8;
- X is OH; ##STR64## CO.sub.2 R.sup.1 wherein R.sup.1 is H or lower alkyl; or ##STR65## wherein Z is H, lower alkyl, or aryl, SO.sub.2 --Q (wherein Q is lower alkyl or aryl), ##STR66## or OR.sup.2 wherein R.sup.2 is H; Y is substituted alkyl (wherein the substituent is halo, lower alkoxy, alkyl-aryl, haloalkyl, cycloalkyl or alkylcycloalkyl) aryl-lower alkyl; alkenyl containing 3 to 6 carbons; alkynyl containing 3 to 6 carbons; aryl (which may be unsubstituted or substituted with lower alkyl, halogen or lower alkoxy), cycloalkyl; substituted cycloalkyl; cycloalkylalkyl, substituted cycloalkylalkyl, or phenoxymethyl;
- wherein alkyl or lower alkyl by itself or as part of another group contains 1 to 12 carbons, cycloalkyl by itself or as part of another group contains 3 to 12 carbons in the ring portion, aryl by itself or as part of another group refers to a monocyclic or bycyclic aromatic ring which contains 6 to 10 carbons in the ring portion, and the cycloalkyl group by itself or as part of another group may be substituted with 1 or 2 halogens, 1 or 2 lower alkyl groups or lower alkoxy groups (the above substituents not being adjacent to sterically hindered groups);
- and represents a single bond or double bond with the proviso that where represents a double bond, A is CH.dbd.CH and B is CH.dbd.CH or (CH.sub.2).sub.2 and Y is other than alkenyl or alkynyl, or a pharmaceutically acceptable salt thereof.
Parent Case Info
This is a division of application Ser. No. 378,547, filed May 17, 1982, which is a continuation-in-part of application Ser. No. 319,511, filed Nov. 9, 1981, abandoned.
US Referenced Citations (7)
Divisions (1)
|
Number |
Date |
Country |
Parent |
378547 |
May 1982 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
319511 |
Nov 1981 |
|